Alprostadil in the Treatment of 42 Patients with Severe Viral Hepatitis

Objective:To survey the curative effects of alprostadil injection in the treatment of severe viral hepatitis. Methods:82 patients with severe viral hepatitis were randomly divided into two groups, the treatment group(42 cases) and the control group(40 cases). Patients of the control group were subjected to routine therapeutic program including hepatinica, jaundice treating drugs as well as symptomatic and supportive treatment. On the basis of the routine therapeutic program, patients of the treatment group were given each a daily Ⅳ instillation of 10 μg of alprostadil injection. The course of treatment lasted 15 days and a second course was ordered when necessary. The therapeutic effects and adverse reactions were kept under observation. Results:The effective rate of the treatment group (69.0%) was higher than that of the control group(47.5%)( P 0.05). The total serum bilirubin(T bil) in patients of the treatment group dropped to a significantly lower level than that of the control group( P 0.05), The level of factor Ⅱ activity significantly higher, and the incidence of hepatorenal syndrome evidently lower in patients of the treatment group than in those of the control group ( P 0.05). Adverse reactions were mild in patients of the treatment group. Conclusion:Alprostadil injection was shown to be effective in the treatment of severe viral hepatitis.